{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estring&page=11",
    "query": {
      "intervention": "Estring",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 887,
    "total_pages": 89,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estring&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estring&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T22:20:38.479Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03324061",
      "title": "Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Fulvestrant for Injectable Suspension",
          "type": "DRUG"
        },
        {
          "name": "Faslodex (Reference)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eagle Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 75 Years · Female only"
      },
      "enrollment_count": 600,
      "start_date": "2017-11-30",
      "completion_date": "2018-07-12",
      "has_results": false,
      "last_update_posted_date": "2021-06-03",
      "last_synced_at": "2026-10-22T22:20:38.479Z",
      "location_count": 12,
      "location_summary": "Long Beach, California • DeLand, Florida • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03324061"
    },
    {
      "nct_id": "NCT05317364",
      "title": "Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obstetric; Injury Pelvic Floor",
        "Sexual Dysfunction",
        "Anal Incontinence",
        "Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "Estradiol 0.01% Vag Cream",
          "type": "DRUG"
        },
        {
          "name": "Placebo vaginal cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 38,
      "start_date": "2022-07-14",
      "completion_date": "2026-02-13",
      "has_results": false,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-10-22T22:20:38.479Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05317364"
    },
    {
      "nct_id": "NCT06250205",
      "title": "Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Obicetrapib",
          "type": "DRUG"
        },
        {
          "name": "Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)",
          "type": "DRUG"
        },
        {
          "name": "Drospirenone / Ethinyl Estradiol (COC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2024-02-05",
      "completion_date": "2024-04-26",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-22T22:20:38.479Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06250205"
    },
    {
      "nct_id": "NCT02761694",
      "title": "Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Vevorisertib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2016-06-26",
      "completion_date": "2021-03-10",
      "has_results": true,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-10-22T22:20:38.479Z",
      "location_count": 6,
      "location_summary": "Las Vegas, Nevada • Oklahoma City, Oklahoma • Charleston, South Carolina + 3 more",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02761694"
    },
    {
      "nct_id": "NCT01455597",
      "title": "Evaluate Long-Term Safety and Efficacy WC3011 (Estradiol Vaginal Cream)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Vulvovaginal Atrophy"
      ],
      "interventions": [
        {
          "name": "WC3011 Estradiol Vaginal Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Warner Chilcott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "35 Years and older · Female only"
      },
      "enrollment_count": 309,
      "start_date": "2011-10-20",
      "completion_date": "2012-12-03",
      "has_results": true,
      "last_update_posted_date": "2022-05-09",
      "last_synced_at": "2026-10-22T22:20:38.479Z",
      "location_count": 64,
      "location_summary": "Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01455597"
    },
    {
      "nct_id": "NCT07784582",
      "title": "Pre-pubertal Low Dose Transdermal Estradiol in Turner Syndrome",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Turner Syndrome",
        "Primary Ovarian Insufficiency"
      ],
      "interventions": [
        {
          "name": "Estradiol transdermal patch 0.025mg/24 hours- 1/8th fractionated patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's National Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "12 Years",
        "sex": "FEMALE",
        "summary": "8 Years to 12 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2026-09-01",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-22T22:20:38.479Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07784582"
    },
    {
      "nct_id": "NCT02195986",
      "title": "A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrophic Vaginitis"
      ],
      "interventions": [
        {
          "name": "Estradiol Vaginal Cream, 0.01%",
          "type": "DRUG"
        },
        {
          "name": "Estrace® 0.01% cream",
          "type": "DRUG"
        },
        {
          "name": "Placebo Vaginal Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 70 Years · Female only"
      },
      "enrollment_count": 366,
      "start_date": "2014-06",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2022-03-09",
      "last_synced_at": "2026-10-22T22:20:38.479Z",
      "location_count": 21,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02195986"
    },
    {
      "nct_id": "NCT03498313",
      "title": "Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Suicidal Ideation"
      ],
      "interventions": [
        {
          "name": "Transdermal Estradiol + Placebo",
          "type": "DRUG"
        },
        {
          "name": "Oral Micronized Progesterone + Placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2018-07-27",
      "completion_date": "2021-05-09",
      "has_results": true,
      "last_update_posted_date": "2022-09-14",
      "last_synced_at": "2026-10-22T22:20:38.479Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03498313"
    },
    {
      "nct_id": "NCT00551733",
      "title": "Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel poliglumex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CTI BioPharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": 450,
      "start_date": "2007-08",
      "completion_date": "2007-12-25",
      "has_results": false,
      "last_update_posted_date": "2020-10-05",
      "last_synced_at": "2026-10-22T22:20:38.479Z",
      "location_count": 41,
      "location_summary": "Scottsdale, Arizona • Burbank, California • Escondido, California + 36 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Montebello",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00551733"
    },
    {
      "nct_id": "NCT01597193",
      "title": "Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "anastrozole",
          "type": "DRUG"
        },
        {
          "name": "exemestane",
          "type": "DRUG"
        },
        {
          "name": "fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 101,
      "start_date": "2012-04-30",
      "completion_date": "2018-01-22",
      "has_results": true,
      "last_update_posted_date": "2019-05-08",
      "last_synced_at": "2026-10-22T22:20:38.479Z",
      "location_count": 17,
      "location_summary": "Aurora, Colorado • Enfield, Connecticut • Sarasota, Florida + 7 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Enfield",
          "state": "Connecticut"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01597193"
    }
  ]
}